

eMeasure Title	Hemoglobin A1c Test for Pediatric Patients		
eMeasure Identifier (Measure Authoring Tool)	148	eMeasure Version number	2
NQF Number	0060	GUID	95fb767e-0cb2-4778-b5ff-6ba9a53fa28e
Measurement Period	January 1, 20xx through December 31, 20xx		
Measure Steward	National Committee for Quality Assurance		
Measure Developer	National Committee for Quality Assurance		
Endorsed By	National Quality Forum		
Description	Percentage of patients 5-17 years of age with diabetes with an HbA1c test during the measurement period		
Copyright	Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA). The Measures are copyrighted but can be reproduced and distributed, without modification, for noncommercial purposes (eg, use by healthcare providers in connection with their practices). Commercial use is defined as the sale, licensing, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial use of the Measures requires a license agreement between the user and NCQA. NCQA is not responsible for any use of the Measures. (c) 2008-2013 National Committee for Quality Assurance. All Rights Reserved. Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code sets should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any CPT or other codes contained in the specifications. CPT(R) contained in the Measure specifications is copyright 2004-2012 American Medical Association. LOINC(R) copyright 2004-2012 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2012 International Health Terminology Standards Development Organisation. ICD-10 copyright 2012 World Health Organization. All Rights Reserved.		
Disclaimer	These performance Measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications. THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND. Due to technical limitations, registered trademarks are indicated by (R) or [R] and unregistered trademarks are indicated by (TM) or [TM].		
Measure Scoring	Proportion		
Measure Type	Process		
Stratification	None		
Risk Adjustment	None		
Rate Aggregation	None		
Rationale	Diabetes mellitus (diabetes) is a group of diseases characterized by high blood glucose levels caused by the body's inability to correctly produce or utilize the hormone insulin. It is recognized as a leading cause of death and disability in the U.S. and is highly underreported as a cause of death. Diabetes may cause life-threatening, life-ending or life-altering complications, including poor circulation, nerve damage or neuropathy in the feet and eventual amputation. Nearly 60-70 percent of diabetics suffer from mild or severe nervous system damage (American Diabetes Association 2009). Even though most target recommendations for glycemic control have been based on data obtained from studies of adult patients with diabetes, the ideal goal of near-normalization of blood glucose levels in children and adolescents is generally the same as that for adults. However, special consideration must be given to the unique risks of hypoglycemia in young children (Silverstein et al. 2005).		
Clinical Recommendation Statement	1. American Association of Clinical Endocrinologists (2002): Recommends that a glycosylated hemoglobin be performed during an initial assessment and during follow-up assessments, which should occur at no longer than three-month intervals. 2. American Diabetes Association (2006): Recommends obtaining a glycosylated hemoglobin during an initial assessment and then routinely as part of continuing care. In the absence of well-controlled studies that suggest a definite testing protocol, expert opinion recommends glycosylated hemoglobin be obtained at least twice a year in patients who are meeting treatment goals and who have stable glycemic control and more frequently (quarterly assessment) in patients whose therapy was changed or who are not meeting glycemic goals.		
Improvement Notation	Higher scores indicate better quality		
Reference	American Diabetes Association. 2009. "Standards of Medical Care in Diabetes-2009." Diabetes Care 2009 32(Suppl 1):S6-S12.		
Reference	American Diabetes Association. 2006. "Standards of medical care in Diabetes-2006." Diabetes Care 29(suppl1):S4-42.		
Reference	American Association of Clinical Endocrinologists. 2002. "Medical Guidelines for the Management of Diabetes Mellitus: The AACE System of Intensive Diabetes Self-Management—2002 Update." Endocr Pract 8(suppl 1):40-82.		
Reference	Silverstein, J., G. Klingensmith, K. Copeland, L. Plotnick, F. Kaufman, L. Laffel, L. Deeb, M. Grey, B. Anderson, L. Holzmeister, N. Clark, 2005. "Care of Children and Adolescents With Type 1 Diabetes. A statement of the American Diabetes Association." Diabetes Care, 28(1), 186-212. http://care.diabetesjournals.org/content/28/1/186.long		
Definition	None		
Guidance	Only patients with a diagnosis of Type 1 or Type 2 diabetes should be included in the denominator of this measure; patients with a diagnosis of secondary diabetes due to another condition should not be included.		
Transmission Format	TBD		
Initial Patient Population	Patients 5 to 17 years of age with a diagnosis of diabetes and a face-to-face visit between the physician and the patient that predates the most recent visit by at least 12 months		

Denominator	Equals Initial Patient Population
Denominator Exclusions	Patients with a diagnosis of gestational diabetes during the measurement period
Numerator	Patients with documentation of date and result for a HbA1c test during the measurement period
Numerator Exclusions	Not Applicable
Denominator Exceptions	None
Measure Population	Not Applicable
Measure Observations	Not Applicable
Supplemental Data Elements	For every patient evaluated by this measure also identify payer, race, ethnicity and sex.

Table of Contents

- [Population criteria](#)
- [Data criteria \(QDM Data Elements\)](#)
- [Reporting Stratification](#)
- [Supplemental Data Elements](#)

Population criteria

- **Initial Patient Population =**
 - AND NOT: "Occurrence A of Diagnosis, Active: Diabetes" ends before start of "Occurrence A of Encounter, Performed: Diabetes Visit"
 - AND: "Patient Characteristic Birthdate: birth date" >= 5 year(s) starts before start of "Measurement Period"
 - AND: "Patient Characteristic Birthdate: birth date" < 17 year(s) starts before start of "Measurement Period"
 - AND: "Occurrence A of Diagnosis, Active: Diabetes" starts before or during (MOST RECENT : "Occurrence A of Encounter, Performed: Diabetes Visit" during "Measurement Period")
 - AND: "Encounter, Performed: Diabetes Visit" >= 12 month(s) starts before start of "Occurrence A of Encounter, Performed: Diabetes Visit"
- **Denominator =**
 - AND: "Initial Patient Population"
- **Denominator Exclusions =**
 - AND NOT: "Occurrence A of Diagnosis, Active: Gestational Diabetes" ends before start of "Measurement Period"
 - AND: "Occurrence A of Diagnosis, Active: Gestational Diabetes" starts before or during "Measurement Period"
- **Numerator =**
 - AND: "Laboratory Test, Result: HbA1c Laboratory Test (result)" during "Measurement Period"
- **Denominator Exceptions =**
 - None

Data criteria (QDM Data Elements)

- "Diagnosis, Active: Diabetes" using "Diabetes Grouping Value Set (2.16.840.1.113883.3.464.1003.103.12.1001)"
- "Diagnosis, Active: Gestational Diabetes" using "Gestational Diabetes Grouping Value Set (2.16.840.1.113883.3.464.1003.103.12.1010)"
- "Encounter, Performed: Diabetes Visit" using "Diabetes Visit Grouping Value Set (2.16.840.1.113883.3.464.1003.103.12.1012)"
- "Laboratory Test, Result: HbA1c Laboratory Test" using "HbA1c Laboratory Test Grouping Value Set (2.16.840.1.113883.3.464.1003.198.12.1013)"
- "Patient Characteristic Birthdate: birth date" using "birth date LOINC Value Set (2.16.840.1.113883.3.560.100.4)"

Reporting Stratification

- None

Supplemental Data Elements

- "Patient Characteristic Ethnicity: Ethnicity" using "Ethnicity CDC Value Set (2.16.840.1.114222.4.11.837)"
- "Patient Characteristic Payer: Payer" using "Payer Source of Payment Typology Value Set (2.16.840.1.114222.4.11.3591)"
- "Patient Characteristic Race: Race" using "Race CDC Value Set (2.16.840.1.114222.4.11.836)"
- "Patient Characteristic Sex: ONC Administrative Sex" using "ONC Administrative Sex Administrative Sex Value Set (2.16.840.1.113762.1.4.1)"

Measure Set	None
--------------------	------